H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...

GH Research PLC (NASDAQ:GHRS) received a reiterated Buy rating and $40.00 price target from H.C. Wainwright, representing significant upside potential for the $936 million market cap company. The ...

Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...

H.C. Wainwright raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $21 from $8 and keeps a Buy rating on the shares. The firm ...

H.C. Wainwright raised the firm’s price target on BlackSky (BKSY) to $20 from $12 and keeps a Buy rating on the shares. The firm says that as ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look ...

H.C. Wainwright analyst Arthur He initiated coverage of Nektar (NKTR) with a Buy rating and $6.50 price target Nektar is a clinical-stage biopharmaceutical company focused on developing innovative ...